Interleukin-6-deficient mice develop mature-onset obesity
- V. Wallenius, K. Wallenius, J. Jansson
- BiologyNature Network Boston
- 2002
The immune-modulating cytokine interleukin-6 (IL-6) is expressed both in adipose tissue and centrally in hypothalamic nuclei that regulate body composition. We investigated the impact of loss of IL-6…
The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes.
- M. S. Winzell, B. Ahrén
- Medicine, BiologyDiabetes
- 1 December 2004
It is concluded that the high-fat diet-fed C57BL/6J mouse model is a robust model for IGT and early type 2 diabetes, which may be used for studies on pathophysiology and development of new treatment.
Autonomic regulation of islet hormone secretion – Implications for health and disease
- B. Ahrén
- Biology, MedicineDiabetologia
- 1 April 2000
It is concluded that islet innervation, through the contribution of all branches of the autonomic nerves and several different neurotransmitters is of importance both for the physiology and pathophysiology of the islets.
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
- T. Nyström, M. Gutniak, Å. Sjöholm
- Medicine, BiologyAmerican Journal of Physiology. Endocrinology and…
- 1 December 2004
It is concluded that GLP-1 improves endothelial dysfunction but not insulin resistance in type 2 diabetic patients with coronary heart disease and adds yet another salutary property of the peptide useful in diabetes treatment.
Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
- M. Gutniak, C. Orskov, J. Holst, B. Ahrén, S. Efendić
- Medicine, BiologyNew England Journal of Medicine
- 14 May 1992
GLIP has an antidiabetogenic effect, and it may therefore be useful in the treatment of patients with NIDDM, indicating that GLIP had an insulinotropic effect.
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes.
- B. Ahrén, M. Landin-Olsson, P. Jansson, M. Svensson, D. Holmes, A. Schweizer
- MedicineJournal of Clinical Endocrinology and Metabolism
- 1 May 2004
Improved metabolic control by DPP-4 inhibition in type 2 diabetes is seen in association with reduced glucagon levels and, despite the lower glycemia, unaltered insulin levels.
Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes
- B. Ahrén
- Biology, MedicineNature reviews. Drug discovery
- 1 May 2009
This Review summarizes islet GPCR expression, signalling and function, and highlights their potential as targets for the treatment of type 2 diabetes.
Gastric Carcinoids: Biologic Behavior and Prognosis After Differentiated Treatment in Relation to Type
- K. Borch, B. Ahrén, H. Ahlman, S. Falkmer, G. Granerus, L. Grimelius
- MedicineAnnals of Surgery
- 1 July 2005
Subtyping of gastric carcinoids is helpful in the prediction of malignant potential and long-term survival and is a guide to management and was poor regarding type 4 carcinoids.
FOXC2 Is a Winged Helix Gene that Counteracts Obesity, Hypertriglyceridemia, and Diet-Induced Insulin Resistance
- A. Cederberg, L. M. Grønning, B. Ahrén, K. Taskén, P. Carlsson, S. Enerbäck
- Biology, MedicineCell
- 7 September 2001
Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study
- T. Jönsson, Y. Granfeldt, S. Lindeberg
- MedicineCardiovascular Diabetology
- 16 July 2009
Over a 3-month study period, a Paleolithic diet improved glycemic control and several cardiovascular risk factors compared to a Diabetes diet in patients with type 2 diabetes.
...
...